Roth Capital Thinks Actinium Pharmaceuticals’ Stock is Going to Recover

By Carrie Williams

Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (NYSE: ATNM) yesterday and set a price target of $5. The company’s shares opened today at $0.98, close to its 52-week low of $0.93.

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -14.0% and a 31.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Applied Genetic Technologies, and ImmunoCellular Therapeutics.

Actinium Pharmaceuticals has an analyst consensus of Moderate Buy.

The company has a one year high of $3.50 and a one year low of $0.93. Currently, Actinium Pharmaceuticals has an average volume of 574.9K.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. Most recently, in August 2016, Memorial Sloan-Kettering Cancer Center, a Major Shareholder at ATNM sold 50,000 shares for a total of $85,495.

Actinium Pharmaceuticals, Inc. operates as a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers. It targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. Its lead radiopharmaceutical Iomab-B will be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company was founded in 1993 and is headquartered in New York, NY.